806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

Authors
Publication date
Publisher
'Ovid Technologies (Wolters Kluwer Health)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      Last time updated on 05/09/2020